Yuhan Corporation

Seyoung Lim

Hyun Ho Choi

Minji Seo

Dohoon Kim

Jong Gyun Kim

Mi Kyeong Ju

Su Youn Nam

Jun Hwan Kim

Ju-Young Park

Seul Gi Kim

Byung Hyun Choi

Jun Kyung Lee

Sangmyoun Lim

The present invention provides a fusion protein comprising an FGF21 mutant protein and an Fc region of an immunoglobulin. The fusion protein according to the present invention exhibits improved pharmacological efficacy, in vivo duration and protein stability, and a pharmaceutical composition comprising the fusion protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.

Long-acting FGF21 fusion proteins and pharmaceutical composition comprising same

The present invention provides a dual function protein prepared by linking a biologically active protein and an FGF mutant protein to an Fc region of an immunoglobulin, which has improved pharmacological efficacy, in vivo duration and protein stability. A dual function protein according to the present invention exhibits improved pharmacological efficacy, in vivo duration and protein stability, and a pharmaceutical composition containing the dual function protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis or cardiovascular diseases.

Dual function proteins comprising FGF21 mutant protein and pharmaceutical composition comprising same

Growing community of inventors

Yongin-si, South Korea

Seyoung Lim